ACT-MBC: A Study of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer (MBC)

Conditions: Metastatic Breast Cancer

Sex: All

Ages: 18 Years – N/A

Enrollment: 65

Sponsor: Menarini Silicon Biosystems, INC

Location: United States

Summary

ACT-MBC prospectively assesses the impact of CTCs on treatment decisions, response assessment and prognosis in MBC patients.

Eligibility Criteria

Inclusion Criteria:Invasive breast cancer with radiographic and/or clinical evidence of advanced metastatic or unresectable diseaseER+/HER2- patients prior to starting 2nd line therapy or beyond OR ER/Progesterone Receptor (PR)/HER2-negative (Triple Negative) patients prior to starting any line of therapyMeasurable and/or non-measurable disease is allowedMale or female breast cancer is allowedAge > 18 yearsWillingness to provide mandatory blood specimensWilling to return to enrolling institution for follow up imaging at least onceExclusion Criteria:Life expectancy of ≤ 6 monthsInability to provide blood samples based on the judgment of the treating provider

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05662345). StuddyBuddy aggregates publicly available trial information.